![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
GW Carter, PR Young, DH Albert, J Bouska, R Dyer, RL Bell, JB Summers and DW Brooks
Immunosciences Research Area, Abbott Laboratories, Illinois.
Zileuton [N-(1-benzo[b]thien-2-ylethyl)-N-hydroxyure] inhibited 5- hydroxyeicosatetraenoic acid synthesis by rat basophilic leukemia cell 20,000 x g supernatant and rat polymorphonuclear leukocytes (PMNL) (IC50 = 0.5 and 0.3 microM) respectively. It also inhibited leukotriene (LT)B4 biosynthesis by rat PMNL (IC50 = 0.4 microM), human PMNL (IC50 = 0.4 microM) and human whole blood (IC50 = 0.9 microM). Inhibition of human PMNL LTB4 biosynthesis was removed readily by a simple wash procedure. At concentrations up to 100 microM, the compound produced little or no inhibition of several related enzymes, such as platelet 12- lipoxygenase, soybean and rabbit reticulocyte 15-lipoxygenase and sheep seminal vesicle cyclooxygenase. At p.o. doses from 0.5 to 5 mg/kg in the dog, zileuton produced a rapid and sustained inhibition of ex vivo blood LTB4 biosynthesis which correlated with the pharmacokinetic behavior of the compound. In a similar ex vivo study in the rat, the compound displayed an p.o. ED50 of 2 mg/kg. Zileuton was highly effective in preventing 6-sulfidopeptide LT formation in the rat peritoneal cavity triggered by an antigen-antibody reaction with an ED50 of 3 mg/kg. In experimental models of inflammation, zileuton significantly reduced arachidonic-acid induced mouse ear edema (ED50 = 31 mg/kg) and also attenuated inflammatory cell accumulation in the rat pleural Arthus reaction. The effectiveness of this compound for preventing LT formation in vitro, ex vivo and in vivo suggests its utility for preventing the pathophysiological effects of the LTs and other 5-lipoxygenase products in animals and in humans.
This article has been cited by other articles:
|
|
 |
|
  S. R. Oliver, V. P. Wright, N. Parinandi, and T. L. Clanton Thermal tolerance of contractile function in oxidative skeletal muscle: no protection by antioxidants and reduced tolerance with eicosanoid enzyme inhibition Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2008; 295(5): R1695 - R1705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Meyer, C. W. McAndrew, and D. J. Donoghue Nordihydroguaiaretic Acid Inhibits an Activated Fibroblast Growth Factor Receptor 3 Mutant and Blocks Downstream Signaling in Multiple Myeloma Cells Cancer Res., September 15, 2008; 68(18): 7362 - 7370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Nieves and J. J. Moreno Hydroxyeicosatetraenoic acids released through the cytochrome P-450 pathway regulate 3T6 fibroblast growth J. Lipid Res., December 1, 2006; 47(12): 2681 - 2689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Li, S. Sood, S. Wang, M. Fang, P. Wang, Z. Sun, C. S. Yang, and X. Chen Overexpression of 5-Lipoxygenase and Cyclooxygenase 2 in Hamster and Human Oral Cancer and Chemopreventive Effects of Zileuton and Celecoxib Clin. Cancer Res., March 1, 2005; 11(5): 2089 - 2096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Collin, A. Rossi, S. Cuzzocrea, N. S. A. Patel, R. Di Paola, J. Hadley, M. Collino, L. Sautebin, and C. Thiemermann Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton J. Leukoc. Biol., November 1, 2004; 76(5): 961 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Chen, S. Wang, N. Wu, S. Sood, P. Wang, Z. Jin, D. G. Beer, T. J. Giordano, Y. Lin, W.-c. J. Shih, et al. Overexpression of 5-Lipoxygenase in Rat and Human Esophageal Adenocarcinoma and Inhibitory Effects of Zileuton and Celecoxib on Carcinogenesis Clin. Cancer Res., October 1, 2004; 10(19): 6703 - 6709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. A. Patel, S. Cuzzocrea, P. K. Chatterjee, R. Di Paola, L. Sautebin, D. Britti, and C. Thiemermann Reduction of Renal Ischemia-Reperfusion Injury in 5-Lipoxygenase Knockout Mice and by the 5-Lipoxygenase Inhibitor Zileuton Mol. Pharmacol., August 1, 2004; 66(2): 220 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Gui and R. E. Carraway Involvement of mast cells in basal and neurotensin-induced intestinal absorption of taurocholate in rats Am J Physiol Gastrointest Liver Physiol, August 1, 2004; 287(2): G408 - G416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Haynes Jr, B. S. Baliga, B. Obiako, S. Ofori-Acquah, and B. Pace Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the L-arginine-nitric oxide signaling pathway Blood, May 15, 2004; 103(10): 3945 - 3950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lu, M. L. Schrag, D. E. Slaughter, C. E. Raab, M. Shou, and A. D. Rodrigues MECHANISM-BASED INHIBITION OF HUMAN LIVER MICROSOMAL CYTOCHROME P450 1A2 BY ZILEUTON, A 5-LIPOXYGENASE INHIBITOR Drug Metab. Dispos., November 1, 2003; 31(11): 1352 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. B. Vargaftig and M. Singer Leukotrienes Mediate Murine Bronchopulmonary Hyperreactivity, Inflammation, and Part of Mucosal Metaplasia and Tissue Injury Induced by Recombinant Murine Interleukin-13 Am. J. Respir. Cell Mol. Biol., April 1, 2003; 28(4): 410 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. B. Vargaftig and M. Singer Leukotrienes, IL-13, and chemokines cooperate to induce BHR and mucus in allergic mouse lungs Am J Physiol Lung Cell Mol Physiol, February 1, 2003; 284(2): L260 - L269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Askonas, J. F. Kachur, D. Villani-Price, C.-D. D. Liang, M. A. Russell, and W. G. Smith Pharmacological Characterization of SC-57461A (3-[Methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic Acid HCl), a Potent and Selective Inhibitor of Leukotriene A4 Hydrolase I: In Vitro Studies J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 577 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Kachur, L. J. Askonas, D. Villani-Price, N. Ghoreishi-Haack, S. Won-Kim, C.-D. D. Liang, M. A. Russell, and W. G. Smith Pharmacological Characterization of SC-57461A (3-[Methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic Acid HCl), a Potent and Selective Inhibitor of Leukotriene A4 Hydrolase II: In Vivo Studies J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 583 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. P. Beierschmitt, J. D. McNeish, R. J. Griffiths, A. Nagahisa, M. Nakane, and D. E. Amacher Induction of Hepatic Microsomal Drug-Metabolizing Enzymes by Inhibitors of 5-Lipoxygenase (5-LO): Studies in Rats and 5-LO Knockout Mice Toxicol. Sci., September 1, 2001; 63(1): 15 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. C. BARNES Effects of Antileukotrienes in the Treatment of Asthma Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): S73 - 76. [Full Text] [PDF]
|
|
|
|
 |
|
 Leukotriene-receptor antagonists and related compounds Can. Med. Assoc. J., November 1, 1999; 161(90111): s31 - 34. [Full Text]
|
|
|
|
 |
|
 X. Zhu, N. M. Munoz, K. P. Kim, H. Sano, W. Cho, and A. R. Leff Cytosolic Phospholipase A2 Activation Is Essential for {beta}1 and {beta}2 Integrin-Dependent Adhesion of Human Eosinophils J. Immunol., September 15, 1999; 163(6): 3423 - 3429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Marleau, B. Fruteau de Laclos, A. B. Sanchez, P. E. Poubelle, and P. Borgeat Role of 5-Lipoxygenase Products in the Local Accumulation of Neutrophils in Dermal Inflammation in the Rabbit J. Immunol., September 15, 1999; 163(6): 3449 - 3458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. E. Steele, C. A. Holmes, E. T. Hawk, L. Kopelovich, R. A. Lubet, J. A. Crowell, C. C. Sigman, and G. J. Kelloff Lipoxygenase Inhibitors as Potential Cancer Chemopreventives Cancer Epidemiol. Biomarkers Prev., May 1, 1999; 8(5): 467 - 483. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Mancuso, T. J. Standiford, T. Marshall, and M. Peters-Golden 5-Lipoxygenase Reaction Products Modulate Alveolar Macrophage Phagocytosis of Klebsiella pneumoniae Infect. Immun., November 1, 1998; 66(11): 5140 - 5146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Salas, J. Panes, J. I. Elizalde, M. Casadevall, D. C. Anderson, D. N. Granger, and J. M. Pique Mechanisms responsible for enhanced inflammatory response to ischemia-reperfusion in diabetes Am J Physiol Heart Circ Physiol, November 1, 1998; 275(5): H1773 - H1781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Machinist, M. D. Mayer, E. M. Roberts, B. W. Surber, and A. D. Rodrigues Identification of the Human Liver Cytochrome P450 Enzymes Involved in the In Vitro Metabolism of a Novel 5-Lipoxygenase Inhibitor Drug Metab. Dispos., October 1, 1998; 26(10): 970 - 976. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. S. Katz, M. Papernik, R. W. Honsinger, J. Churg, A. Churg, M. E. Wechsler, and J. M. Drazen Zafirlukast and Churg-Strauss Syndrome JAMA, June 24, 1998; 279(24): 1949 - 1950. [Full Text] [PDF]
|
|
|
|
|
|
J. J. Bouska, R. L. Bell, C. L. Goodfellow, A. O. Stewart, C. D. W. Brooks, and G. W. Carter Improving the In Vivo Duration of 5-Lipoxygenase Inhibitors. Application of an In Vitro Glucuronosyltransferase Assay Drug Metab. Dispos., September 1, 1997; 25(9): 1032 - 1038. [Abstract] [Full Text]
|
|
|
|
|
|
R. L. Bell, R. R. Harris, P. E. Malo, J. B. Bouska, T. K. Shaughnessy, K. I. Hulkower, C. D. W. Brooks, and G. W. Carter ABT-761 Attenuates Bronchoconstriction and Pulmonary Inflammation in Rodents J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1366 - 1373. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
